CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 185 enrolled
Drug / intervention
Placebo Inhalation Powder +4 moredrug
Likely dose
Prednisolone Oral Capsule 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01086410
NCT01086410Phase 3Completed
CompareCT.gov

Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 Versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics

GlaxoSmithKline·interventional·Posted Mar 15, 2010·Updated Jan 18, 2017

In Brief

A Phase 3 clinical trial evaluating Placebo Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, and 2 other interventions for Asthma. Completed, enrolled 185 participants across 17 sites in 3 countries.

Detailed Summary

The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, Poland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2010
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.3 years ago

Interventions

Placebo Inhalation Powderdrug

Placebo Inhalation powder inhaled once daily for 6 weeks' treatment

Fluticasone Furoate/GW642444 Inhalation Powderdrug

Dose B inhaled once daily for 6 weeks' treatment

Fluticasone Furoate/GW642444 Inhalation Powderdrug

Dose A inhaled once daily for 6 weeks' treatment

Placebo Oral Capsuledrug

One placebo capsule taken each day on the last 7 days of the study

Prednisolone Oral Capsuledrug

Prednisolone 10mg oral capsule taken each day on the last 7 days of the study